NCT05816603RecruitingPhase 2
Transcranial Direct Current Stimulation for Post-stroke Fatigue
Home-based Post-stroke Fatigue Treatment Using Transcranial Direct Current Stimulation (tDCS)
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
The investigators hypothesize that delivery of anodal tDCS to the left frontal head region will reduce fatigue severity following stroke.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 3 Apr 2023
- Start date
- 23 May 2023
- Primary completion date
- Dec 2027
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Stroke
- NCT number
- NCT05816603
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 24
- From 23 May 2023 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of seizure
- History of moderate to severe traumatic brain injury
- A score of less than 21 on the MoCA suggesting major neurocognitive disorder.
- Signs of skin rash, infection, or laceration in the supraorbital region where the tDCS will be applied.
- Other major neurological, medical, or psychiatric illnesses that could confound results in the opinion of the site investigator.
Other
- Metal in the head (except mouth) or implanted cranial or thoracic devices (i.e. pacemaker, DBS stimulator)
- A score of 10 or more on the PHQ-9 or GAD-7 scale, suggestive of moderate to severe depression/anxiety.
- Inability to provide informed consent
Who the study is looking for
- Male or female patients aged \>18 years
- Greater than 3 months from first hemorrhagic or ischemic stroke (subacute to chronic), confirmed through neuroimaging (CT or MRI).
- Fatigue severity score average \>4 (severe fatigue)
- Willingness to remain stable on pharmacologic therapy through the duration of the study.
- Availability of a caregiver, family member, or friend to be present during the administration of the tDCS intervention.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weill Cornell Medicine, 525 E. 68th St, Baker Pavilion, F-2106 Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.